LeMaitre (LMAT) - Multiplikator forward rega marang pendapatan
The forward P/S trend confirms the conservative development of the LeMaitre Vascular, Inc. (LMAT) R&D pipeline. Pricing power within the vascular implant niche and high margins on direct sales ensure price stability. Business scalability relies on the global distribution of patented devices with significant markups. The current value is 5.90, which allows for a real-time assessment of the company's future sales value.
LeMaitre Vascular - rincian analitis lan metrik utama (LMAT)
- rega pasar lan target rega analis:
- indikator kapitalisasi pasar:
- rincian valuasi buku bisnis:
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas LeMaitre Vascular, Inc.|LMAT - Rasio utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas LeMaitre Vascular, Inc.|LMAT - Tanggungan utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku LeMaitre|LMAT - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan LeMaitre Vascular|Rasio cepet lemaitre.com
- data bathi bisnis lan rasio investasi:
LMAT - Penghasilan resik perusahaan|Bathi sing dikarepake LeMaitre Vascular, Inc.|LMAT - Koefisien rega marang bathi|Pangali Forward P/E LeMaitre Corp|LMAT - Pangali PEG|Pangali EV/EBITDA LeMaitre|LMAT - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan LeMaitre Vascular|LMAT - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan lemaitre.com|LMAT - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep LeMaitre Vascular, Inc.
- data dodolan lan asil:
Analisis umum perusahaan:LMAT (LeMaitre Corp)
To identify stability drivers, investors must correlate market capitalization with projected revenue, as the expected P/S ratio serves as an indicator of whether the asset is overbought or undervalued. This metric's trend allows for an assessment of the fair value of LeMaitre Vascular, Inc. (LMAT), given the company's monopoly position in the vascular surgery segment and the lack of alternatives to its specialized operating room instrumentation.
Analisis perusahaan pesaing
Rasio rega marang prakiraan pendapatan Intuitive Surgical Inc ISRG|Multiplikator Forward P/S Danaher Corporation Inc. DHR|BDX - Rasio rega marang prakiraan pendapatan|STERIS plc (STE) - Multiplikator forward rega marang pendapatan|WST: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Baxter International Inc. (BAX)|MASI (masimo.com) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Stevanato Group Corp STVN|Multiplikator forward rega marang pendapatan TFX (Teleflex Inc)|Merit Medical - Kapitalisasi marang prakiraan pendapatan|Envista Holdings - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake ICUI (ICU Medical Inc)|XRAY - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake AtriCure Corp ATRC|staar.com (STAA) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan ChromaDex Corporation|ZIMV (ZimVie Inc) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan ANGO (AngioDynamics)|Rasio rega marang prakiraan pendapatan Cerus Corp (CERS)|TKNO: Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Monogram Technologies Inc. MGRM|Rega forward marang dodolan STSS|INFU - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan UTMD (Utah Medical Products Inc.)|KORU Medical Systems Inc. (KRMD) - Rasio rega marang prakiraan pendapatan|Nyxoah S.A. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Microbot Medical, Inc.|Kapitalisasi marang prakiraan pendapatan PDEX (Pro-Dex)|Rasio rega marang prakiraan pendapatan Zentek (ZTEK)|Rasio kapitalisasi marang dodolan sing dikarepake Elutia Inc|Multiplikator Forward P/S MLSS (milestonescientific.com)|NXGL: Kapitalisasi marang prakiraan pendapatan|Retractable Tech - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Harvard Bioscience Inc. HBIO|FEMY: Multiplikator Forward P/S|MeihuaMed - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Predictive Oncology Inc|callanjmb.com (CJMB) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Atrion Corporation (ATRI)|Rasio kapitalisasi marang dodolan sing dikarepake neurometrix.com
